After prior therapy* for advanced renal cell carcinoma (RCC), CHARGE FORWARD WITH THE POWER OF 3 SECONDARY ENDPOINT PRIMARY ENDPOINT SECONDARY ENDPOINT Median Overall Survival (OS) 1 : Median Progression-free Survival (PFS) 1 † : Objective Response Rate (ORR) 1 † : 21.4 vs 16.5 months months 7.4 months vs 3.8 months 17 % vs 3 % (CABOMETYX™) (everolimus) ( P <0.0001); partial responses only (CABOMETYX™) (everolimus) (CABOMETYX™) (everolimus) HR=0.66 (95% CI: 0.53-0.83); ( P =0.0003) HR=0.58 (95% CI: 0.45-0.74); ( P <0.0001) †Conﬁ rmed per independent radiology review committee (IRRC). CABOMETYX™ is the only single agent to demonstrate signiﬁ cant improvement across 3 endpoints—OS, PFS, and ORR—in advanced RCC after prior treatment.* *Anti-angiogenic therapy. : Palmar-Plantar Erythrodysesthesia Syndrome (PPES) occurred with : �e;4-(# Strong CYP3A4 Inducers . Increase the dosage of CABOMETYX if CABOMETYX. Withhold CABOMETYX in patients who develop intolerable concomitant use with strong CYP3A4 inducers cannot be avoided. Grade 2 PPES or Grade 3 PPES until improvement to Grade 1; resume USE IN SPECIFIC POPULATIONS CABOMETYX at a reduced dose. : �e;#4(1$  lactating woman not to breastfeed during CABOMETYX treatment : Reversible Posterior Leukoencephalopathy Syndrome (RPLS) and for 4 months after the ﬁ nal dose. occurred in the cabozantinib clinical program. Evaluate for RPLS in : ,. 2($,215(2'+(*#2-+-#$0 2$ Hepatic Impairment , reduce the patients presenting with seizures, headache, visual disturbances, CABOMETYX dosage. CABOMETYX is not recommended for use in patients confusion, or altered mental function. Discontinue CABOMETYX in with severe hepatic impairment. patients who develop RPLS. : Embryo-fetal Toxicity may be associated with CABOMETYX. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during CABOMETYX treatment and for 4 months after the last dose. ADVERSE REACTIONS The most commonly reported (≥25%) adverse reactions were diarrhea, fatigue, nausea, decreased appetite, PPES, hypertension, vomiting, weight decreased, and constipation. DRUG INTERACTIONS : �e;4-(# Strong CYP3A4 Inhibitors . Reduce the dosage of CABOMETYX if concomitant use with strong CYP3A4 inhibitors cannot be avoided. Please see Brief Summary of the Prescribing Information for CABOMETYX™ on adjacent pages. Reference: 1. CABOMETYX™ (cabozantinib) Prescribing Information. Exelixis, Inc., 2016.